MDL | MFCD00866152 |
---|---|
Molecular Weight | 244.26 |
Molecular Formula | C15H13FO2 |
SMILES | O=C(O)[C@@H](C)C1=CC=C(C2=CC=CC=C2)C(F)=C1 |
COX-1 0.48 μM (IC 50 ) |
COX-2 0.47 μM (IC 50 ) |
(S)-Flurbiprofen (10 –7 M) results in a total suppression of basal and stimulated PGE2 release in rat skin [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
NCT Number | Sponsor | Condition | Start Date | Phase |
---|---|---|---|---|
NCT03434197 | Taisho Pharmaceutical Co., Ltd. |
Osteoarthritis Knee Pain
|
February 5, 2018 | Phase 3 |
NCT04908748 | Teikoku Seiyaku Co., Ltd.|Clinsearch GmbH|CRM Biometrics GmbH|Clinigen GmbH |
Soft Tissue Injuries|Contusions|Strains|Sprains|Bruises
|
May 20, 2021 | Phase 2 |
NCT02729207 | Teikoku Seiyaku Co., Ltd. |
Ankle Sprain
|
July 2016 | Phase 2 |
NCT04505787 | SocraTec R&D GmbH|Teikoku Seiyaku Co., Ltd.|SocraMetrics GmbH |
Comparative Bioavailability
|
July 24, 2020 | Phase 1 |
Solid
Room temperature in continental US; may vary elsewhere.
Powder | -20°C | 3 years |
---|---|---|
4°C | 2 years | |
In solvent | -80°C | 6 months |
-20°C | 1 month |
DMSO : 100 mg/mL ( 409.40 mM ; Need ultrasonic)
Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
---|
1 mM | 4.0940 mL | 20.4700 mL | 40.9400 mL |
5 mM | 0.8188 mL | 4.0940 mL | 8.1880 mL |
10 mM | 0.4094 mL | 2.0470 mL | 4.0940 mL |